Kyoungwon Baik

List of Publications by Year
in descending order

36	428	759190	839512
papers	citations	12 h-index	18 g-index

38	38	38	605
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Extensive frontal focused ultrasound mediated bloodâ€“brain barrier opening for the treatment of Alzheimerâ€™s disease: a proof-of-concept study. Translational Neurodegeneration, 2021, 10, 44.	8.0	46
2	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. Nutrition, 2021, 83, 111090.	2.4	36
3	Dopaminergic modulation of restingâ€state functional connectivity in de novo patients with Parkinson's disease. Human Brain Mapping, 2014, 35, 5431-5441.	3.6	30
4	Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinsonâ€™s disease. Brain, 2021, 144, 1127-1137.	7.6	30
5	Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia. Neurobiology of Aging, 2020, 89, 63-70.	3.1	24
6	White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 1411-1419.	3.9	22
7	Effects of statins on dopamine loss and prognosis in Parkinsonâ€™s disease. Brain, 2021, 144, 3191-3200.	7.6	22
8	Factor analysisâ€“derived cognitive profile predicting early dementia conversion in PD. Neurology, 2020, 95, e1650-e1659.	1.1	21
9	Effects of dopaminergic depletion and brain atrophy on neuropsychiatric symptoms in de novo Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 197-204.	1.9	19
10	Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment. Neurology, 2021, 97, e1110-e1122.	1.1	18
11	Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease. Movement Disorders, 2020, 35, 2240-2249.	3.9	17
12	White matter hyperintensities and risk of levodopaâ€induced dyskinesia in Parkinsonâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 229-238.	3.7	16
13	Dural Arteriovenous Fistula Manifested as Rapid Progressive Dementia Successfully Treated by Endovascular Embolization Only. Neurointervention, 2017, 12, 50-53.	0.8	12
14	Donepezil for mild cognitive impairment in Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 4734.	3.3	10
15	Sexâ€dependent association of urate on the patterns of striatal dopamine depletion in Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 773-778.	3.3	9
16	Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-NaÃ¯ve Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1-10.	2.8	9
17	Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. Neurobiology of Aging, 2021, 106, 45-54.	3.1	9
18	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 4203-4212.	3.6	8

#	Article	IF	Citations
19	Effects of baseline serum uric acid and apolipoprotein E4 on longitudinal cognition and cerebral metabolism. Neurobiology of Aging, 2021, 106, 223-231.	3.1	8
20	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. Scientific Reports, 2021, 11, 14394.	3.3	7
21	Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-naÃ¯ve Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 1-7.	2.2	7
22	Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism. Annals of Neurology, 2022, 91, 853-863.	5.3	7
23	Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinsonâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2242-2248.	3.6	5
24	Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. Stem Cells International, 2021, 2021, 1-10.	2.5	5
25	Sexâ€specific association of urate and levodopaâ€induced dyskinesia in Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 1948-1956.	3.3	5
26	Structural connectivity networks in Alzheimerâ€™s disease and Lewy body disease. Brain and Behavior, 2021, 11, e02112.	2.2	4
27	Implication of Small Vessel Disease MRI Markers in Alzheimerâ€™s Disease and Lewy Body Disease1. Journal of Alzheimer's Disease, 2021, 83, 545-556.	2.6	3
28	Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 129-136.	2.8	3
29	White matter connectivity networks predict levodopa-induced dyskinesia in Parkinsonâ€™s disease. Journal of Neurology, 2022, 269, 2948-2960.	3.6	3
30	The pattern of FP-CIT PET in pure white matter hyperintensitiesâ€“related vascular parkinsonism. Parkinsonism and Related Disorders, 2021, 82, 1-6.	2.2	2
31	Microstructural Connectivity is More Related to Cognition than Conventional MRI in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 239-249.	2.8	2
32	Effect of Alzheimerâ€™s Disease and Lewy Body Disease on Metabolic Changes. Journal of Alzheimer's Disease, 2021, 79, 1471-1487.	2.6	2
33	Different patterns of Î²-amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. Neurobiology of Aging, 2021, 101, 199-206.	3.1	2
34	Effects of Alzheimerâ€™s genetic risk scores and CSF biomarkers in de novo Parkinsonâ€™s Disease. Npj Parkinson's Disease, 2022, 8, 57.	5.3	2
35	Diffusion tensor imagingâ€based pontine damage as a degeneration marker in synucleinopathy. Journal of Neuroscience Research, 2021, 99, 2922-2931.	2.9	1
36	Effects of APOE4 on Alzheimerâ€™s disease, Lewy body disease, cerebral amyloid deposition and cognitive dysfunction. Alzheimer's and Dementia, 2020, 16, e037300.	0.8	0